Development of a customized diagnostic test for lung cancer

多胺途径已被证明在癌细胞中显著上调。我们的行业合作伙伴BioMark Diagnostics公司的初步研究表明，多胺途径的代谢物可能作为肺癌的可靠诊断生物标志物。在我们之前资助的NSERC Engage项目中，我们通过液相色谱-质谱（LC-MS）分析测量了肺癌中的多胺代谢物。还测量了许多其他代谢物，包括脂质、生物胺和氨基酸。生物信息学和统计分析显示，与单独使用多胺代谢物相比，其中4种代谢物增加了诊断肺癌的敏感性和特异性。基于这项工作和与BioMark的咨询，我们已经确定了13种能够区分对照（健康）和肺癌样本的代谢物生物标志物。

The polyamine pathway has been demonstrated to be significantly up-regulated in cancer cells. Preliminary studies by our industry collaborator, BioMark Diagnostics Inc, have indicated that metabolites of the polyamine pathway may serve as robust diagnostic biomarkers for lung cancer. In our previously funded NSERC Engage project, we measured polyamine metabolites in lung cancer by liquid chromatography-mass spectrometry (LC-MS) analysis. A number of other metabolites were also measured, including lipids, biogenic amines, and amino acids. Bioinformatics and statistical analysis revealed that the inclusion of 4 of these additional metabolites increased the sensitivity and specificity for diagnosing lung cancer compared to the sensitivity and specificity provided by the polyamine metabolites alone. Based on this work and consultation with BioMark, we have identified 13 metabolite biomarkers that were able to distinguish between control (healthy) and lung cancer samples.